"Viking Therapeutics' Weight-Loss Pill Shows Promising Phase 1 Results, Stocks Soar"
TL;DR Summary
Viking Therapeutics' stock surged over 25% after reporting positive Phase 1 results for its oral weight-loss drug, showing up to 5.3% weight loss in patients with minimal side effects. The company plans to launch the drug into Phase 2 trials later this year, following strong results from its injectable version. Analysts view the data as a "clear win" and believe the drug has best-in-class potential, positioning it to compete with current market leaders in the weight-loss drug space.
Topics:business#businesshealthcare#oral-glp-1-option#phase-1-results#stock-market#viking-therapeutics#weight-loss-drug
- Viking Therapeutics stock rises on positive oral obesity drug Phase 1 data Yahoo Finance
- Viking Therapeutics stock jumps more than 25% on promising weight loss pill data CNBC
- Oral obesity drug from Viking Therapeutics hits key early target STAT
- Trump Media, Viking Therapeutics and Krispy Kreme stocks send markets higher Quartz
- Viking Touts Promising Phase I Data for Weight-Loss Pill BioSpace
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
77%
344 → 78 words
Want the full story? Read the original article
Read on Yahoo Finance